Astellas Pharma China, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1994-10-14
- Employees
- -
- Market Cap
- -
- Website
- https://www.astellas.com.cn
Clinical Trials
28
Active:3
Completed:19
Trial Phases
4 Phases
Phase 1:5
Phase 2:1
Phase 3:7
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 4
12 (48.0%)Phase 3
7 (28.0%)Phase 1
5 (20.0%)Phase 2
1 (4.0%)A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients
Phase 4
Completed
- Conditions
- Liver TransplantationKidney Transplantation
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05153915
- Locations
- 🇨🇳
Site CN86003, Beijing, China
🇨🇳Site CN86006, Changsha, China
🇨🇳Site CN86001, Guangzhou, China
A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients
Phase 4
Completed
- Conditions
- Kidney TransplantationLiver Transplantation
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05152628
- Locations
- 🇨🇳
Site CN86003, Beijing, China
🇨🇳Site CN86002, Guangzhou, China
🇨🇳Site CN86001, Shanghai, China
A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
Phase 2
Active, not recruiting
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- Drug: Enfortumab vedotin
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04995419
- Locations
- 🇨🇳
Site CN86001, Beijing, China
🇨🇳Site CN86009, Changsha, China
🇨🇳Site CN86002, Guangzhou, China
A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04793204
- Locations
- 🇨🇳
Site CN86001, Bei'jing, China
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 249
- Registration Number
- NCT04562090
- Locations
- 🇨🇳
Site CN86020, Wuhan, Hubei, China
🇨🇳Site CN86001, Beijing, China
🇨🇳Site CN86004, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found